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Abstract: The use of amorphous drug delivery systems is an attractive approach to improve the
bioavailability of low molecular weight drug candidates that suffer from poor aqueous solubility.
However, the pharmaceutical performance of many neat amorphous drugs is compromised by their
tendency for recrystallization during storage and lumping upon dissolution, which may be improved
by the application of coatings on amorphous surfaces. In this study, hot melt coating (HMC) as a
solvent-free coating method was utilized to coat amorphous carvedilol (CRV) particles with tripalmitin
containing 10% (w/w) and 20% (w/w) of polysorbate 65 (PS65) in a fluid bed coater. Lipid coated
amorphous particles were assessed in terms of their physical stability during storage and their drug
release during dynamic in vitro lipolysis. The release of CRV during in vitro lipolysis was shown to
be mainly dependent on the PS65 concentration in the coating layer, with a PS65 concentration of 20%
(w/w) resulting in an immediate release profile. The physical stability of the amorphous CRV core,
however, was negatively affected by the lipid coating, resulting in the recrystallization of CRV at the
interface between the crystalline lipid layer and the amorphous drug core. Our study demonstrated
the feasibility of lipid spray coating of amorphous CRV as a strategy to modify the drug release from
amorphous systems but at the same time highlights the importance of surface-mediated processes for
the physical stability of the amorphous form.
Keywords: hot melt coating (HMC); amorphous solids; solid-state; amorphous stability; amorphous
drug delivery; dynamic in vitro lipolysis; carvedilol; tripalmitin
1. Introduction
With an increasing amount of lipophilic or hydrophobic low molecular weight drug candidates
emerging from the pipelines of the pharmaceutical industry, pharmaceutical scientists are continuously
confronted with the issue of poor aqueous drug solubility [1]. To enable a sufficient bioavailability
of these drugs after oral administration, various formulation strategies have been developed [2,3],
among which the conversion of the crystalline state of the drug into a high energy amorphous form
has gained significant attention over the past decades [4–6]. Due to their high internal energy, most
amorphous drug formulations exhibit the desired increase in solubility, which however is compromised
by their tendency to recrystallize, often preventing their market access [7]. Consequently, the research
focus was laid on the identification of factors that influence the physical stability of amorphous drugs.
In this context, the mobility of molecules on amorphous surfaces has been found to play a major
role in the physical stability of the amorphous form [8]. Due to their weaker or fewer intermolecular
interactions at the solid-gas interphase and the resulting greater freedom of movement, molecules on
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the surface of amorphous solids are up to a million times more mobile than in the bulk [9]. Moreover,
high molecular mobility on amorphous surfaces was found to correlate with the speed of surface
crystal growth, resulting in fast recrystallization of the amorphous form [10].
To address the challenge of surface-induced recrystallization, different approaches have been
investigated to slow down surface mobility of amorphous drugs [11], including the application of
surface coatings. Wu et al. (2006) demonstrated that covering an amorphous indomethacin surface by
glass slides significantly improved the physical stability of the amorphous form compared to samples
with an air-exposed surface [10]. Different methods have since been established that mimic a more
realistic coating process, for example, gold sputter coating [12–14] and layer-by-layer polyelectrolyte
coating [14]. Despite the positive results of the above-mentioned techniques in preventing the
crystallization of amorphous surfaces, the used materials were still lacking pharmaceutical relevance.
To overcome this limitation, further studies utilized biopolymers which were deposited on amorphous
surfaces by dip-coating from aqueous solutions based on electrostatic interactions, such as alginate
on clofazimine [15], dextran sulfate on loratadine [16], gelatin on indomethacin and nifedipine [17],
and chitosan on indomethacin [18]. The coating of amorphous materials with biopolymers not
only resulted in improved physical stability but also was able to improve its powder flowability and
dissolution performance [18]. In a recent study by Novakovic et al. (2020), the polymer coating approach
from aqueous solutions was translated into a spray coating method using the pharmaceutically relevant
polymer polyvinylpyrrolidone (PVP) for the coating of amorphous indomethacin compacts [19].
In contrast to the established use of PVP as an excipient for the preparation of amorphous solid
dispersions, the direct targeting of the amorphous surface by coating with PVP reduces the overall
polymer burden and enables a higher drug loading of the final dosage form. Moreover, the study
demonstrated the feasibility of a scalable industrial process, like spray-coating, for the coating of
amorphous solids and at the same time delaying the onset of recrystallization of the amorphous form.
While certain amorphous drugs tolerate temporary exposure to aqueous solvents (see above),
others tend to recrystallize immediately after contact [20]. Consequently, the use of aqueous coating
solutions cannot be considered a “one-fits-all” approach. Priemel et al. (2013) demonstrated that
a simple dry physical mixture of amorphous indomethacin and polymer particles of an amino
methacrylate copolymer (Eudragit E) could lead to the increased physical stability of the amorphous
form, as long as the polymer could form a coherent coat on the amorphous surface [21]. Similar
results were obtained by utilizing vibrational ball milling for the dry coating of the fast recrystallizing
amorphous drug acetaminophen with carnauba wax [22]. Another solvent-free coating method that,
in contrast to vibrational ball milling, enables a precise and scalable coating process, is hot melt coating
(HMC) [23]. During HMC, the molten coating material is sprayed onto the substrate and solidifies
on the substrate surface upon contact, forming a coherent coating layer [24]. Coating materials used
in HMC applications are generally lipid-based excipients like waxes, hydrogenated vegetable oils,
and their derivatives, e.g., fatty acids, partial glycerides, and polyoxylglycerides [23]. Lipid-based
excipients are well suited for the HMC process due to their low melting points (<80 ◦C) and melt
viscosities, compared for example, to synthetic polymers, which enable a continuous delivery of coating
material by peristaltic pumps into the coating chamber [25]. Due to the hydrophobic character of HMC
excipients, a prolonged-release from the coated material is achieved and can be modified towards an
immediate release by the combination with surfactants or other more hydrophilic components [26].
Apart from the modification of release profiles, lipid coatings are widely used for taste masking [27],
swallowability improvement, and moisture protection of oral formulations [28].
To our knowledge, no investigation of the HMC of amorphous solids and its impact on the
physical stability and/or release from the coated amorphous material has been reported. In this study,
we utilize a fluid bed hot-melt coating setup for the coating of amorphous carvedilol (CRV) with the
aim to investigate the feasibility of lipid spray coating on amorphous surfaces and its impact on the
physical stability and drug release during in vitro lipid digestion of the coated amorphous particles.
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2. Materials and Methods
2.1. Materials
Carvedilol (CRV) was purchased from Cipla Ltd. (Mumbai, India) and Polysorbate 65 (Tween
65) was obtained from Croda Euro Ltd. (Fogras de la Selva, Spain). Tripalmitin (Dynasan 116) was
kindly provided by IOI Oleo (Witten, Germany). Soy phospholipid (S-PC) was obtained from Lipoid
(Ludwigshafen, Germany) and maleic acid, tris base, 4-bromobenzeneboronic acid (4-BBBA), bovine
bile extract (B-3883) and porcine pancreatic lipase extract (P-1625) were purchased from Sigma–Aldrich
(Saint Louis, MO, USA). Sodium chloride (NaCl), sodium hydroxide, potassium dihydrogen phosphate,
and calcium chloride dihydrate were purchased from Merck (Darmstadt, Germany). Methanol (MeOH,
HPLC grade) and acetonitrile (ACN, HPLC grade) were obtained from VWR (Herlev, Denmark).
2.2. Methods
2.2.1. Preparation of Starting Materials
To obtain amorphous CRV as starting material for the HMC process, crystalline CRV was placed
in aluminum pans and heated to 130 ◦C in a heating oven until a clear, crystal-free melt was formed.
Subsequently, the pan was placed on an ice bath to facilitate the quench cooling of the molten CRV.
The obtained amorphous CRV was equilibrated at ambient temperature and humidity for 30 min,
followed by a manual grinding step using a mortar and pestle. The ground amorphous CRV was
subsequently sieved into a particle size fraction ranging from 355–800 µm.
2.2.2. Hot Melt Coating and Sample Storage
Hot melt coating of amorphous CRV particles in a fluid bed was performed at the RCPE in Graz
using a Ventilus V-2.5 laboratory-scale system equipped with an Innojet IHD-1 hot melt device (Romaco
Innojet GmbH, Steinen, Germany) (schematic provided in Supplementary Materials Figure S1). A batch
size of 180 g of sieved amorphous CRV particles was used as core material for the coating trials.
The following process parameters were used: 5 g/min spray rate, 1.1 bar atomizing air pressure,
45 m3/h airflow, 80 ◦C spray air temperature, and an inlet air temperature 25 ± 0.1 ◦C. Two different
coating compositions were used: Tripalmitin containing 10% (w/w) PS65 (10% (w/w) PS65) and 20%
(w/w) PS65 (20% (w/w) PS65). The theoretical coating mass ratio was set to 50% (w/w). Uncoated
amorphous CRV particles and the coated products were stored at room temperature under dry (silica
gel) and humid (75% rH, saturated NaCl solution) conditions. A third portion of the samples was
vacuum-sealed and stored frozen at −20 ◦C to maintain fresh product conditions for the following
in vitro evaluation. The obtained samples were shipped under controlled temperature and humidity
conditions to Copenhagen for further analysis. The physical stability of coated and uncoated amorphous
CRV particles was probed at regular intervals by X-ray powder diffraction (XRPD).
2.2.3. Particle Size Analysis
The particle size of coated and uncoated amorphous CRV particles was analyzed using a QICPIC
high-speed image analysis sensor (Sympatec GmbH, Clausthal-Zellerfeld, Germany) that was coupled
to a RODOS/L dry disperser unit. A feeding rate of 30% with an injector diameter of 4 mm and an air
pressure of 1 bar was used. Particle projections were captured at a frequency of 400 frames per second.
The particle size was evaluated by calculating the diameter of a circle of equal projection area (EQPC).
2.2.4. Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) was carried out to study the thermal response of coated
and uncoated amorphous CRV particles using a Discovery DSC (TA Instruments, New Castle, DE,
USA). A sample mass of 3–5 mg was transferred to Tzero aluminum pans and sealed with pierced Tzero
hermetic lids. All measurements were carried out using a heating rate of 10 ◦C/min from a starting
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temperature of −10 ◦C to an end temperature of 130 ◦C under a nitrogen gas flow of 50 mL/min. The
obtained thermograms were analyzed with TRIOS software (TA Instruments, New Castle, DE, USA).
2.2.5. X-ray Powder Diffraction
The physical stability of coated and uncoated amorphous CRV particles was analyzed by X-ray
powder diffraction (XRPD) using a PANalytical X’Pert PRO X-ray diffractometer (PANalytical, Almelo,
The Netherlands) with Cu Kα radiation (λ = 1.542 Å, current 40 mA, voltage 45 kV), operated in
reflection mode. The samples were placed on aluminum sample holders and scanned from 5 to 35◦
(2θ) using a scan speed of 0.0673◦ s−1 and a step size of 0.0263◦ (2θ). Mercury 4.3.1 (CCDC, Cambridge,
UK) software was used to calculate the theoretical diffractogram of the crystalline hydrate form of
CRV, as no pure CRV hydrate crystals were obtained experimentally.
2.2.6. Scanning Electron Microscopy and Energy-Dispersive X-ray Spectrometry
To study the morphology of coated and uncoated amorphous CRV particles, scanning electron
microscopy (SEM) images were acquired using a Hitachi TM3030 tabletop microscope (Hitachi
High-Technologies Europe GmbH, Krefeld, Germany) operated at an accelerating voltage of 15 kV.
Samples were sputter-coated with gold (Cressington 108 auto, Cressington Scientific Instruments,
Watford, UK) prior to SEM analysis.
The CRV distribution inside the stored coated amorphous CRV particles was studied by elemental
mapping of cross-sections for the characteristic X-ray peak of nitrogen. The elemental distributions were
investigated by environmental scanning electron microscopy (FEI Quanta 200 ESEM FEG, Hillsboro,
OR, USA) combined with energy-dispersive X-ray (EDX) spectroscopy using an Oxford Instruments
80 mm2 X-Max silicon drift detector. The EDX images were analyzed using AZtecLive software (Oxford
Instruments, Bristol, UK).
2.2.7. Dynamic In Vitro Lipolysis
The release of CRV from coated and uncoated amorphous particles was studied using a dynamic
in vitro lipolysis method that was previously described by Zangenberg et al. (2001) with minor
modifications [29]. The amorphous particles were added to a temperature-controlled glass vessel (37
◦C) resulting in a total CRV mass of 25 mg for each lipolysis run. A volume of 25 mL FaSSIF (tris-maleate
buffer 2 mM, pH 6.5, bile salt 2.95 mM, phospholipids 0.26 mM, sodium chloride 50 mM) was added
to the lipolysis vessel, which was equipped with an electrical stirrer. Lipid digestion was initiated
after 1 min of predispersion by adding 5 mL of freshly prepared pancreatic extract (600 USP/mL) to
the lipolysis vessel. To control the rate of lipolysis, calcium (0.5 M) was added at a continuous rate of
0.01 mL/min. The drop in pH, caused by the release of free fatty acids (FFA), was compensated by
dosing a 0.4 M NaOH solution using a pH-stat apparatus (Metrohm Titrino 744, Tiamo Version 1.3,
Herisau, Switzerland) to maintain a pH of 6.5 during the total run time of the experiment (120 min).
Samples were withdrawn after 1, 5, 15, 30, 60, 90, and 120 min, and the lipase activity in the collected
samples was immediately inhibited by the addition of 5 µl 4-BBBA (1 M, dissolved in MeOH). After
centrifugation at 17,000 g for 15 min and appropriate dilution with ACN, the solubilized amount of
CRV in the supernatant was quantified using HPLC.
2.2.8. Coating Mass Ratio Determination
The determination of the coating mass ratio was carried out by HPLC analysis. Approximately
40 mg of the coated amorphous CRV particles were dissolved in 10 mL of MeOH. To ensure complete
dissolution of CRV and disintegration of the coating shell, samples were ultrasonicated in a Branson
5510 ultrasonic bath (Branson Ultrasonics, Danbury, CT, USA) for 10 min and subsequently centrifuged
at 17,000 g for 15 min. The concentration of CRV in the supernatant was quantified by HPLC after
appropriate dilution with ACN.
Pharmaceutics 2020, 12, 519 5 of 13
2.2.9. HPLC
The samples obtained during dynamic in vitro lipolysis and the determination of the core-to-shell
mass ratio were analyzed using an Agilent 1260 Infinity chromatographic system (Agilent Technologies,
Santa Clara, CA, USA) equipped with an ACE C18 column (Advanced Chromatography Technologies
Ltd., Aberdeen, Scotland). The mobile phase consisted of acetonitrile and phosphate buffer (0.02 M,
pH 2) (50:50% (v/v)) at a flow rate of 1.0 mL/min. The eluted CRV was detected at a wavelength of
242 nm.
3. Results and Discussion
3.1. Particle Characterization
Particles obtained after the manual grinding process and sieving of amorphous CRV showed an
irregular particle shape with sharp edges (Figure 1b). The average particle size of the amorphous CRV
starting material measured by high-speed image analysis was 676.2 ± 23.8 µm (10% (w/w) PS65) and
608.4 ± 33.0 µm (20% (w/w) PS65), respectively. In general, starting material particle sizes above 100 µm
are desired for hot melt coating purposes to enable sufficient fluidization during the coating process [23].
The hot melt coating process with a theoretical coating mass of 50% (w/w) resulted in a particle size
increase to 824.4 ± 23.9 µm (10% (w/w) PS65) and 890.3 ± 28.2 µm (20% (w/w) PS65), respectively
(Figure 1a). As shown by the representative SEM images in Figure 1c,d, the formation of a coherent
coating layer was achieved, despite the irregular shape of the amorphous CRV starting material.
To further evaluate the resulting coating mass ratio, the CRV content of coated particles was quantified
by HPLC. The obtained results were close to the theoretical value of 50% (w/w), with 45.2 ± 1.9% (10%
(w/w) PS65) and 45.4 ± 1.7% (20% (w/w) PS65). The similar values obtained for both batches indicated a
sufficient reproducibility of the coating process, leading to a coating mass ratio close to the targeted
value. The data obtained from the coating mass ratio determination suggested a more homogenous
coating result compared to the particle size analysis. This discrepancy can be explained by the irregular
shape of the coated particles, leading to an under- or overestimation of the particle size increase. Ideally,
particles should be as spherical as possible to aid the formation of a homogeneous coating layer [23].
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images of an uncoated amorphous CRV particle (b), a CRV particle coated with 10% (w/w) PS65 (c), and a
CRV particle coated with 10% (w/w) PS65 as a cross-section including a representative determination of
the coating layer thickness in (d).
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3.2. Physical Stability Study
3.2.1. Solid-State Characterization of Amorphous Particles Using XRPD
The solid-state of the uncoated and coated amorphous CRV particles during storage was assessed
by XRPD. As shown in Figure 2a,b, diffractograms of uncoated amorphous CRV starting material
showed an amorphous halo, confirming the initial amorphous nature before the coating process.
Uncoated amorphous CRV particles were physically stable at ambient temperature for 32 days at dry
conditions and 52 days at 75% rH, respectively. Upon recrystallization, the samples stored at humid
conditions showed characteristic Bragg peaks at 8.30, 8.48, 14.23, 17.36, and 22.05◦ (2θ), corresponding to
the crystalline hydrate form of CRV, whereas storage under dry conditions resulted in recrystallization
of the amorphous CRV into its anhydrous polymorphic form II with characteristic diffractions at 5.78,
13.01, 14.83, 20.35, and 27.55◦ (2θ) [30]. As shown in Figure 2b, unexpectedly, humid storage conditions
delayed the onset of recrystallization of the uncoated amorphous CRV but resulted in a higher degree
of crystallinity after 10 months of storage as shown by the higher diffraction intensities compared
to the samples stored at dry condition, indicating different recrystallization kinetics of the different
polymorphic forms.
In contrast to uncoated amorphous CRV, all coated particles showed diffractions corresponding
to the anhydrous crystalline form II (dry storage) or the crystalline hydrate form (humid storage) of
CRV already during the first measurements after the hot melt coating process, which were performed
immediately after the sample shipment to Copenhagen (within 3–8 days after production, Figure 2).
These results are indicating a decrease in the physical stability of the amorphous CRV compared to the
uncoated samples. Due to the fast recrystallization of the coated particles, no conclusions about the
impact of PS65 content or storage humidity on the physical stability of the coated particles could be
drawn. However, it could be concluded that the applied lipid coating did not protect the amorphous
CRV core from high humidity conditions. The crystalline hydrate form of CRV was only detected in
samples that were stored at 75% rH, enabling the required water uptake for the observed hydrate
formation. Coating formulations of tripalmitin and PS65 have previously been shown to be able to take
up significant amounts of water due to the more hydrophilic character of PS65 (HLB 10.5) compared
to the triglyceride tripalmitin [31]. To obtain effective protection of the coated particles from storage
humidity, neat tripalmitin as the coating material would have to be used. However, this would lead to
a strong retarding effect of the drug release, thus the amount of PS65 in the coating composition has to
be carefully balanced between humidity protection and the desired release profile.
In addition to the detected crystalline CRV diffractions in coated particles, characteristic diffractions
for the stableβ-polymorph of tripalmitin at 19.4, 23.1, and 24.05◦ (2θ) were observed [32]. These findings
indicate a fast conversion from the unstable α–polymorph (Supplementary Materials Figure S2) to
the stable β-polymorph of tripalmitin after the coating process, which previously was found to be
important for a reproducible release profile from the coated formulation during its shelf life [24].
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distribution of CRV inside the coated amorphous particles, which was expected to provide valuable
information about a potential mixing between the drug core and coating layer that might have occurred
during the recrystallization process. As shown in the SEM image in Figure 3a, three distinct layers with
contrast differences were observed, indicating differences in chemical composition. After 8 months of
storage at dry conditions, the amorphous core of the coated particle was still clearly visible and showed
no morphological indication for recrystallization emerging from the center of the particle. The lipid
coating layer adjacent to the amorphous core separated into two different layers, which were not
present in coated samples stored at −20 ◦C (Figure 3b), indicating recrystallization of the amorphous
drug upon storage and not during the coating process itself. To verify the suspected recrystallization
of amorphous CRV, resulting in a mixed layer comprised of crystalline CRV and the coating excipients,
EDX analysis was performed. Due to the absence of nitrogen in the chemical structures of tripalmitin
and PS65 and its presence in CRV (Supplementary Materials Figure S3), the detection of characteristic
Kα radiation from nitrogen atoms was chosen as a marker for CRV. It is evident from spectra 1 and 2
in Figure 3a, that nitrogen was detected in the core and the mixed layer, but not in the outer coating
layer. These results indicate a CRV crystal growth emerging from the surface of the amorphous core
and growing toward the outer coating layer. The crystalline nature of the CRV detected in the mixed
layer was confirmed by XRPD measurements (Section 3.2.1). Previous studies have demonstrated the
ability of amorphous solids to grow crystals in an upward direction without penetrating the bulk,
fed by a highly mobile layer of surface molecules [33]. This hypothesis is further supported by the
surface area ratio between the amorphous core and the outer coating layers, as estimated from the SEM
image in Figure 3a, indicating a reduced mass of the amorphous core due to the crystal growth into the
surrounding lipid layer. Additionally, EDX mapping was performed on a representative measurement
window covering all three layers. As previously suggested by the local spectra (Figure 3a), and in
contrast to the outer layer, nitrogen was detected in the amorphous core and mixed layer, as visualized
by the purple coloring in Figure 3a.
3.3. Probing the Thermal Properties of Amorphous Particles by DSC
The thermal analysis of neat amorphous CRV showed a glass transition at 38.6 ◦C, which was
in accordance with previously published results [34]. During further heating, no recrystallization or
melting event was observed (Figure 4a). For coated amorphous CRV particles (20% (w/w) PS65) a
weak and broad melting endotherm with the onset at 22.1 ◦C was measured, corresponding to the
melting temperature (Tm) of PS65 [31] that was not detected for particles coated with 10% (w/w) PS65,
indicating the limit of detection of the employed method (Figure 4b,c). Upon further heating, the glass
transition of the amorphous CRV core was detected, which was slightly increased compared to uncoated
amorphous CRV (40.0 ◦C for 10% (w/w) PS65 and 44.0 ◦C for 20% (w/w) PS65) and followed by a weak
endothermic event owing to the structural relaxation of the amorphous form during storage [35]. The
melting onset of the coating’s main component, tripalmitin occurred at 59.7 ◦C (10% (w/w) PS65) and
60.4 ◦C (20% (w/w) PS65), respectively, corresponding to the thermodynamically stable β-polymorph
of tripalmitin [24]. The detection of the β-polymorph in coated amorphous CRV samples was in
agreement with the XRPD measurements described in Section 3.2.1. For coated amorphous particles
(10% (w/w) PS65) a small melting endotherm at approx. 91 ◦C was detected, which corresponds to the
melting of the CRV hydrate form (Supplementary Materials Table S1). The detection of CRV hydrate
in the dry-stored coated samples was unexpected, but suggested a mixed crystallization behavior of
amorphous CRV into both polymorphic forms, with the quantity of the formed crystalline hydrate
form staying below the limit of detection of the XRPD measurements in Section 3.2.1. In contrast
to the uncoated amorphous CRV, a broad recrystallization exotherm for coated particles with an
onset temperature of approx. 94 ◦C was observed, followed by a melting event with an onset at
110.3 ◦C (10% (w/w) PS65) and 111.9 ◦C (20% (w/w) PS65), respectively, corresponding to the Tm of the
polymorphic form II of CRV. The observed values were slightly lower than those measured for the pure
crystalline CRV II (Supplementary Materials Figure S4) and the previously reported value of 115 ◦C
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by Prado et al. (2014) [30]. These deviations could be explained by the overlapping recrystallization
and melting events, making a precise determination of the Tm onset more difficult. Moreover, the
melting enthalpy of crystalline CRV was larger compared to the preceding recrystallization enthalpy,
indicating the presence of crystalline CRV in coated particles at the time of DSC analysis, as also
previously detected by XRPD in Section 3.2.1. It can be assumed that the crystalline drug content acted
as a seed for recrystallization upon heating of the amorphous core that was not evident in uncoated
amorphous CRV. However, no conclusions about the ability of the crystalline lipid coating alone to
initiate recrystallization of the amorphous fraction could be made, due to the presence of crystalline
CRV at the point of the first DSC measurement. Additional DSC studies, investigating the thermal
behavior of neat amorphous CRV in combination with the coating excipients, could provide valuable
information about possible interactions between the coating material and amorphous CRV that led to
the recrystallization of the amorphous drug during storage, as observed in the physical stability study
in Section 3.2.
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of FFA from the tripalmitin coating containing 20% (w/w) PS65 was detected, with a delayed release
of FFA from tripalmitin containing 10% (w/w) PS65. A decreased amount of hydrophilic pores not
only reduced the contact area for the aqueous media to the drug core but also might have affected the
accessibility of the pancreatic lipase to the tripalmitin, resulting in a delayed release of FFA for the
10% (w/w) PS65 coating. However, it can be suspected that the PS65 content has a greater impact on
the drug release than the lipid digestion itself, as the maximum drug concentration for uncoated and
coated amorphous particles (20% (w/w) PS65) was reached during the first 30 min of in vitro lipolysis,
a time point where no significant lipid digestion was measured.
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during dynamic in vitro lipolysis of uncoated amorphous CRV particles (circle) and coated amorphous
CRV particles (10% (w/w) PS65 (square) and 20% (w/w) PS65 (cross)). The titration of FFA released
during dynamic in vitro lipolysis of lipids present in blank FaSSIF is shown by the asterisk. Results are
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4. Conclusions
The current study demonstrated the feasibility of coati us drug particles with
lipid excipients in a fluid bed coater by a solvent-fre hot elt c ti r . coherent coating
layer of tripalmitin containing 10% (w/w) and 20% (w/w) of PS65 on the surface of neat amorphous CRV
particles was achieved. Dynamic in vitro lipolysis studies demonstrated the ability of the pancreatic
lipase to digest the coating layer and showed an immediate release profile from amorphous particles
coated with a high PS65 concentration. The applied coating had a negative impact on the physical
stability of the amorphous core in comparison to uncoated amorphous CRV particles during storage
and resulted in the formation of the crystalline CRV hydrate when being exposed to high relative
humidity, indicating a permeability for the moisture of the coating layer. SEM-EDX analysis suggested
the recrystallization of amorphous CRV at the interface between the crystalline lipid coating layer
and the amorphous core, with CRV crystals growing in an upward direction while retaining the
amorphous character of the remaining CRV core. These results highlight the importance of surfaces
mediated processes for the physical stability of the amorphous form. Further studies will investigate
lipid/emulsifier recrystallization as a potential trigger for the recrystallization of amorphous drugs.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/6/519/s1,
Figure S1: Schematic of the coating instrument, Figure S2: XRPD diffractograms of reference materials, Figure S3:
Chemical structures of CRV, tripalmitin and PS65, Figure S4: DSC ther ograms of reference materials, Table S1:
Detected thermal events in reference materials.
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